A pilot program aimed at reducing Medicaid drug spending has limitations, according to a multi-institutional research team including faculty from Weill Cornell Medicine.
Weill Cornell Medicine investigators have “reverse engineered” ketamine’s antidepressant effects to identify potential new strategies for treating depression.